- Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol 2020;38(16):1763-1773.
Background
What do we already know about this topic?
- Approximately 15% of patients present with resectable or borderline resectable pancreatic cancer.
- The benefit of neoadjuvant chemoradiotherapy in this patient group over upfront surgery is controversial.
- The initial results from PREOPANC trial failed to demonstrate a survival benefit of neoadjuvant chemoradiotherapy.1
- This paper reports the long-term results of the PREOPANC trial.
How was this study conducted?
- The PREOPANC trial was an investigator-initiated, nationwide, multicenter, randomized controlled trial (RCT) conducted in 16 Dutch centers and including 248 patients with resectable or borderline resectable pancreatic cancer.
- Patients were randomly assigned (1:1) to neoadjuvant gemcitabine-based chemoradiotherapy followed by surgery or to upfront surgery, both followed by adjuvant gemcitabine.
- The primary endpoint was overall survival (OS) by intention-to-treat (ITT).
